EGFR and cancer: Interestingly, in one of our recent studies, we found that broad drug resistance of cancers can be overcome by low‐dose bortezomib.[47] EGFR‐targeted inhibitors (afatinib, gefitinib, erlotinib, and dacomitinib) and mTOR inhibitors (everolimus and temsirolimus) also had good responses in a portion of PDO lines.